Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00497991 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia
A Phase 1 study of Myeloid Leukemia, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
- 10
- Study locations
NCT00497991: Completed Phase 1 study of Myeloid Leukemia, sponsored by AstraZeneca.
NCT00497991 is a Phase 1 study of Myeloid Leukemia that has completed, run by AstraZeneca. The registered enrollment target is 65 participants, roughly in line with the 70-participant average among 6 other Myeloid Leukemia trials with a reported enrollment target. The trial reports 10 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00497991, a Phase 1 study of Myeloid Leukemia, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to assess safety and tolerability of multiple ascending doses of AZD1152 and to assess effect of AZD1152 on the rate of complete remission in patients with relapsed acute myeloid leukaemia.
Conditions Studied
Interventions
- DRUG AZD1152
Study Locations (10)
Other
- Research Site - Angers
- Research Site - Grenoble
- Research Site - Le Chesnay
- Research Site - Bologna
- Research Site - Roma
- Research Site - Amsterdam
- Research Site - Nijmegen
- Research Site - Rotterdam
New York
- Research Site - New York
Texas
- Research Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2006-05 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
What the finished NCT00497991 record still lists
NCT00497991 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, roughly in line with the 70-participant average among 6 other Myeloid Leukemia trials with a reported enrollment target.
The record links to 1 condition, with Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which AZD1152 is the first listed.
NCT00497991 lists 10 locations in 3 states (Other, New York, Texas).
Frequently Asked Questions
What is clinical trial NCT00497991 about?
NCT00497991 is a clinical study titled "Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia". The purpose of this study is to assess safety and tolerability of multiple ascending doses of AZD1152 and to assess effect of AZD1152 on the rate of complete remission in patients with relapsed acute myeloid leukaemia.
What is the current status of trial NCT00497991?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2006-05. Estimated completion is 2010-04.
What conditions does trial NCT00497991 study?
This clinical trial studies the following conditions: Myeloid Leukemia.
What interventions are being tested in trial NCT00497991?
The interventions under investigation include: AZD1152 (DRUG).
Who is sponsoring clinical trial NCT00497991?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00497991 being conducted?
This trial has 10 study locations across New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
RECRUITING · Phase 1
-
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
RECRUITING · Phase 1
-
A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
RECRUITING · Phase 2
-
Integrated Actionable Aging Assessment for Cancer Patients Pilot
ACTIVE NOT RECRUITING · NA
-
Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia